Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|March 14, 2017
Access to High Cost Drugs Remains a Challenge in Specialty
Author(s)Lauren Santye, Assistant Editor
Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.
Advertisement
Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
2
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
3
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
4
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
5